Pay in 4 interest-free payments of $6.79 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
Carcinogenesis 42 , 14111419 (2021)
Eligibility includes: Adults with obesity (BMI of 30 or higher) Adults with overweight (BMI of 27 or higher) who also have a weight-related condition, such as: High blood pressure Type 2 diabetes Dyslipidemia A medical evaluation is required to determine eligibility and to rule out contraindications
Clinical trials consistently show weight loss averaging 15-17% of starting body weight over 68 weeks of treatment
A study published in 2025 looked at 150 people diagnosed with IBD and obesity who took semaglutide for weight loss
US$ 25.32
US$ 20.82
US$ 28.98
US$ 20.97
